Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: Is it helpful to policy makers?

Seminars in Hematology

Volumn 36, Issue SUPPL. 2, 1999, Pages 26-29

  Bennett, C L ^a   Weinberg, P O ^a   Golub, R M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE POLICY; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTHEMIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II; COST-BENEFIT ANALYSIS; HUMANS; MODELS, ECONOMIC; PLATELET AGGREGATION INHIBITORS; POLICY MAKING; QUINAZOLINES; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 0032900768     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)